> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer Wins Priority Review Voucher for Paxlovid
- URL: https://www.fdaweb.com/pfizer-wins-priority-review-voucher-for-paxlovid/
- Published: 2024-05-24T12:00:00.000Z
- Updated: 2026-09-14T14:31:48.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157055

*Federal Register* notice: FDA is issuing a priority review voucher to Pfizer after determining that its Paxlovid (nirmatrelvir co-packaged with ritonavir) tablets meet the criteria for a material threat medical countermeasure product application. The drug was approved 5/2023 for treating mild-to-moderate Covid-19\. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-11643.pdf?ref=fdaweb.com).